Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: A meta-analysis involving 18 studies

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5921-5930

  Gu, Zhenwei ^a   Wang, Gang ^a   Chen, Weiguo ^b  

^a Department of Orthopedics   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

ER ; Meta analysis; Polymorphism; Prostate cancer

Indexed keywords

ESTROGEN RECEPTOR ALPHA;

ALLELE; ARTICLE; CANCER RISK; DNA POLYMORPHISM; ETHNICITY; GENETIC MODEL; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION SITE; SENSITIVITY ANALYSIS;

DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA-CYTOSINE METHYLASES; ESTROGEN RECEPTOR ALPHA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK;

EID: 84904717890     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1785-4     Document Type: Article

References (54)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. doi:10.3322/caac.20107.
2. Kimura T. East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer. 2012;31:421-9. doi:10.5732/cjc.011.10324.
3. Delgado PO, Alves BC, Gehrke Fde S, Kuniyoshi RK, Wroclavski ML, Del Giglio A, et al. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol. 2013;34:983-6. doi:10.1007/s13277- 012-0634-6.
4. McDougall JA, Li CI. Trends in distant-stage breast, colorectal, and prostate cancer incidence rates from 1992 to 2004: potential influences of screening and hormonal factors. Horm Cancer. 2010;1:55-62. doi:10.1007/s12672- 009-0002-1.
5. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;167:948-51.
6. Rhodes L, Ding VD, Kemp RK, Khan MS, Nakhla AM, Pikounis B, et al. Estradiol causes a dose-dependent stimulation of prostate growth in castrated beagle dogs. Prostate. 2000;44:8-18. (Pubitemid 30390060)
7. Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem. 2004;91:491-503. doi:10.1002/jcb.10759.
8. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008;73:233-44. doi:10.1016/j.steroids.2007.10.013.
9. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009;55:533-42. doi:10.1016/j.eururo.2008.10.035.
10. Ellem SJ, Risbridger GP. The dual, opposing roles of estrogen in the prostate. Ann N YAcad Sci. 2009;1155:174-86. doi:10.1111/j.1749-6632.2009.04360. x.
11. Slater M, Brown D, Husband A. In the prostatic epithelium, dietary isoflavones from red clover significantly increase estrogen receptor beta and E-cadherin expression but decrease transforming growth factor beta1. Prostate Cancer Prostatic Dis. 2002;5:16-21. doi:10.1038/sj.pcan.4500546. (Pubitemid 34257302)
12. Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol. 2004;92:297-305. doi:10.1016/j.jsbmb.2004. 10.016. (Pubitemid 40136584)
13. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem. 1997;272:19858-62. (Pubitemid 27340081)
14. Safarinejad MR, Safarinejad S, Shafiei N. Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphismin prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog. 2012;51 Suppl 1:E104-17. doi:10.1002/mc.21870.
15. Li N, Dong J, Hu Z, Shen H, Dai M. Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;121:177-84. doi:10.1007/s10549-009-0532-9.
16. Guo H, Ming J, Liu C, Li Z, Zhang N, Cheng H, et al. A common polymorphism near the ESR1 gene is associated with risk of breast cancer: evidence froma case-control study and ameta-analysis. PLoS One. 2012;7:e52445. doi:10.1371/journal.pone.0052445.
17. Leigh Pearce C, Near AM, Butler JL, Van Den Berg D, Bretsky P, Conti DV, et al. Comprehensive evaluation of ESR2 variation and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:393-6. doi:10.1158/1055-9965.epi-07- 2512. (Pubitemid 351272792)
18. Einarsdottir K, Darabi H, Czene K, Li Y, Low YL, Li YQ, et al. Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival. Br J Cancer. 2009;100:1358-64. doi:10.1038/sj.bjc.6604984.
19. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res. 2001;7:3092-6. (Pubitemid 32963829)
20. Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED, et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:165-8. doi:10.1158/1055-9965. epi-06-0689. (Pubitemid 46174281)
21. Sonoda T, Suzuki H, Mori M, Tsukamoto T, Yokomizo A, Naito S, et al. Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men. Eur J Cancer Prev. 2010;19:131-7. doi:10.1097/CEJ.0b013e328333fbe2.
22. Jurecekova J, Sivonova MK, Evinova A, Kliment J, Dobrota D. The association between estrogen receptor alpha polymorphisms and the risk of prostate cancer in Slovak population. Mol Cell Biochem. 2013;381:201-7. doi:10.1007/s11010-013-1703-x.
23. Ding X, Cui FM, Xu ST, Pu JX, Huang YH, Zhang JL, et al. Variants on ESR1 and their association with prostate cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:3931-6.
24. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011;71:985-97. doi:10.1002/pros.21314.
25. Winters SJ, Brufsky A, Weissfeld J, Trump DL, Dyky MA, Hadeed V. Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism. 2001;50:1242-7. doi:10.1053/meta.2001.26714. (Pubitemid 33034710)
26. Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, et al. Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood of male neonates. Cancer Epidemiol Biomarkers Prev. 2009;18:1484-91. doi:10.1158/1055-9965.EPI-08-0817.
27. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. STrengthening the REporting of Genetic Association studies (STREGA)-an extension of the STROBE statement. Eur J Clin Invest. 2009;39:247-66.
28. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123-37. doi:10.1002/gepi.20048.
29. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med. 1987;316:450-5. doi:10.1056/NEJM198702193160806. (Pubitemid 17035572)
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test.BMJ. 1997;315:629-34. (Pubitemid 27387172)
31. Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O- methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer. 2003;98:1411-6. doi:10.1002/cncr.11639. (Pubitemid 37151495)
32. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R. Polymorphisms of estrogen receptor alpha in prostate cancer. Mol Carcinog. 2003;37:202-8. doi:10.1002/mc.10138. (Pubitemid 36959536)
33. Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T, Suzuki H, et al. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res. 2004;24:2431-7. (Pubitemid 39166328)
34. Hernandez J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, Thompson IM, et al. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol. 2006;175:523-7. doi:10.1016/s0022-5347(05)00240-5. (Pubitemid 43067344)
35. Low YL, Taylor JI, Grace PB, Mulligan AA, Welch AA, Scollen S, et al. Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer. 2006;56:31-9. doi:10.1207/s15327914nc5601-5. (Pubitemid 46173412)
36. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:969-78. doi:10.1158/1055-9965.epi-06- 0767. (Pubitemid 46910099)
37. Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, Axelsson CK, Gronholdt ML, Grande P, et al. Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis. Circulation. 2007;115:861-71. doi:10.1161/ circulationaha.106.615567. (Pubitemid 46294727)
38. Onsory K, Sobti RC, Al-Badran AI, Watanabe M, Shiraishi T, Krishan A, et al. Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Mol Cell Biochem. 2008;314:25-35. doi:10.1007/s11010- 008-9761-1.
39. Sobti RC, Gupta L, Singh SK, Seth A, Kaur P, Thakur H. Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genet Cytogenet. 2008;185:78-85. doi:10.1016/j.cancergencyto. 2008.04.022.
40. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:1869-80. doi:10.1158/1055-9965.epi-09-0076.
41. Gupta L, Thakur H, Sobti RC, Seth A, Singh SK. Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population.Mol Cell Biochem. 2010;335:255-61. doi:10.1007/s11010- 009-0275-2.
42. Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, et al. Estrogen receptor alpha and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab. 2011;96:E368-72. doi:10.1210/jc.2010-2070.
43. Szendroi A, Speer G, Tabak A, Kosa JP, Nyirady P, Majoros A, et al. The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calciumin the pathogenesis of prostate cancer. Can J Urol. 2011;18:5710-6.
44. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21:427-33. (Pubitemid 30137927)
45. Wigle DT, Turner MC, Gomes J, Parent ME. Role of hormonal and other factors in human prostate cancer. J Toxicol Environ Health B Crit Rev. 2008;11:242-59. doi:10.1080/10937400701873548. (Pubitemid 351451260)
46. Parnes HL, Thompson IM, Ford LG. Prevention of hormone-related cancers: prostate cancer. J Clin Oncol. 2005;23:368-77. doi:10.1200/JCO.2005.08.027. (Pubitemid 46206884)
47. Mononen N, Seppala EH, Duggal P, Autio V, Ikonen T, Ellonen P, et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res. 2006;66:743-7. doi:10.1158/0008-5472.CAN-05-1723. (Pubitemid 43165937)
48. Shimada N, Iwasaki M, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, et al. Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet. 2009;54:209-15. doi:10.1038/jhg.2009.13.
49. Wang F, Zou YF, Feng XL, Su H, Huang F. CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate. 2011;71:1167-77. doi:10.1002/pros.21332.
50. Li Q, Zhu Y, He J, Wang M, Zhu M, Shi T, et al. Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis. Mol Biol Rep. 2013;40:3597-608. doi:10.1007/s11033-012-2434-x.
51. Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G, et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate. 2004;59:69-76. doi:10.1002/pros. 10358. (Pubitemid 38387844)
52. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997;89:166-70. (Pubitemid 27034793)
53. Ross RK, Paganini-Hill A, Henderson BE. The etiology of prostate cancer: what does the epidemiology suggest? Prostate. 1983;4:333-44. (Pubitemid 13011608)
54. Shin HR, Masuyer E, Ferlay J, Curado MP. Cancer in Asia-incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac J Cancer Prev. 2010;11 Suppl 2:11-6.